ArticleFrontiers in physiology2026
A novel circulating osteoimmunological signature for diagnosis: integrating CXCL2, FYN, galectin-3, and STING in postmenopausal osteoporosis.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune ageing in skeletal fragility: clonal haematopoiesis and failure of inflammatory resolution during fracture repair.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The emerging field of bone immunology has clarified the intricate interactions between the immune system and bone metabolism. This investigation was designed to examine changes in concentrations of critical immune cytokines-C-X-C motif chemokine ligand 2 (CXCL-2), FYN (a Src family nonreceptor tyrosine kinase), Galectin-3 (a β-galactoside-specific lectin), and stimulator of interferon genes (STING)-in postmenopausal osteoporotic women, and to explore their potential as biomarkers for early diagnosis of postmenopausal osteoporosis (PMOP). Methods: Between June and September 2025, researchers recruited 100 postmenopausal women diagnosed with osteoporosis and 100 with osteopenia from the Third Hospital of Hebei Medical University, who were subsequently allocated to the Osteoporosis and Osteopenia groups, respectively. Concentrations of CXCL-2, FYN, Galectin-3, and STING were ascertained employing enzyme-linked immunosorbent assay (ELISA) across all study groups. Results: Within the Osteoporosis group, CXCL-2 and FYN concentrations demonstrated marked elevation relative to the NC group, whereas Galectin-3 and STING concentrations showed marked reduction (P < 0.05). Pearson correlation and multiple linear regression analyses revealed that CXCL-2, FYN, Galectin-3, and STING levels were strongly associated with BMD. ROC analysis demonstrated that Galectin-3 exhibited the greatest diagnostic precision for PMOP, with an area under the curve (AUC) of 0.881. Additionally, the combined diagnostic performance of all four factors surpassed that of any single marker. Conclusion: CXCL-2, FYN, Galectin-3, and STING, as immune-related molecules, are integral to bone immune regulation and are closely associated with the pathogenesis of PMOP, positioning them as potential biomarkers for its early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.